A phase 1 trial combining revumenib, an oral menin inhibitor, with standard azacitidine and venetoclax demonstrated high complete remission rates in patients with acute myeloid leukemia harboring NPM1 or KMT2A gene alterations. The UNC Lineberger Comprehensive Cancer Center-led study spanned multiple sites and informed the design of a randomized phase 3 trial. This regimen targets specific genetic subtypes of AML and represents a potential advancement in personalized leukemia therapy.